Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blue Dream is a Sativa-dominant hybrid cannabis strain originating from California, created by crossing the Blueberry and Haze cultivars. It is distinguished by its complex chemical profile, primarily featuring Delta-9-tetrahydrocannabinol (THC) as the lead psychoactive constituent, alongside a specific terpene ensemble including myrcene, alpha-pinene, and beta-caryophyllene. The strain exerts its effects through the activation of the endocannabinoid system, specifically acting as an agonist at the CB1 receptors in the central nervous system and CB2 receptors in the peripheral tissues. Blue Dream is frequently utilized in medicinal contexts for the symptomatic relief of chronic pain, neuropathic pain, depression, and nausea, providing a balance of invigorating cerebral effects and physical analgesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Blue Dream.